Innovation Pharmaceuticals Inc. (IPIX)
OTCMKTS
· Delayed Price · Currency is USD
0.0003
+0.0002 (200.00%)
May 16, 2025, 11:19 AM EDT
Innovation Pharmaceuticals Employees
Innovation Pharmaceuticals had 4 employees as of June 30, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$655,000
Market Cap
158.63K
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 9 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Innovation Pharmaceuticals News
- 1 year ago - Innovation Pharmaceuticals Announces New Milestone at BeaMed; On Track to File 510(k) Submission to FDA in Q2 2024 - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Provides Update on U.S. Patent Applications Covering Use of Brilacidin in Inflammatory Bowel Diseases, Coronaviruses and Fungal Diseases - GlobeNewsWire
- 2 years ago - Innovation Pharma Announces BeaMed Technologies Breakthrough in Development of Fiber Optic Probes for StingRay Laser System; Paves Way for Groundbreaking Integration Testing - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Brilacidin Antifungal Research Published in Nature Communications - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Visits BeaMed; New StingRay Laser System for Epilepsy and Brain Tumors Moving Toward FDA Submission - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter into a Definitive Strategic Development Agreement - GlobeNewsWire
- 2 years ago - Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis - GlobeNewsWire